ARTICLE | Product Development
Surrogate start
What Probiodrug’s Phase IIa results suggest about new biomarkers in AD
July 21, 2017 9:47 PM UTC
Phase II results for Probiodrug AG’s Alzheimer’s disease candidate point to potential surrogate markers for improvements in cognition that one day could be used in early development to handicap the likelihood of success in Phase III.
A major challenge in AD drug development has been the lack of biomarkers that can be easily assessed in early trials and that correlate with clinically meaningful outcomes like improvements in cognition and/or memory...
BCIQ Company Profiles
BCIQ Target Profiles